These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37802418)

  • 1. Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degeneration.
    Singh A; Panhelainen A; Voutilainen MH
    Neurosci Lett; 2023 Nov; 816():137510. PubMed ID: 37802418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegeneration.
    Singh A; Panhelainen A; Reunanen S; Luk KC; Voutilainen MH
    Eur J Neurosci; 2024 Jan; 59(1):132-153. PubMed ID: 38072889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo.
    Wu Q; Shaikh MA; Meymand ES; Zhang B; Luk KC; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2020 Dec; 140(6):831-849. PubMed ID: 33021680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System.
    Björklund A; Nilsson F; Mattsson B; Hoban DB; Parmar M
    J Parkinsons Dis; 2022; 12(8):2307-2320. PubMed ID: 36189605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
    Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
    Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex.
    Boutros SW; Raber J; Unni VK
    J Parkinsons Dis; 2021; 11(3):1091-1115. PubMed ID: 34057097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.
    Tapias V; Hu X; Luk KC; Sanders LH; Lee VM; Greenamyre JT
    Cell Mol Life Sci; 2017 Aug; 74(15):2851-2874. PubMed ID: 28534083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons.
    Er S; Hlushchuk I; Airavaara M; Chmielarz P; Domanskyi A
    J Vis Exp; 2020 Aug; (162):. PubMed ID: 32865527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits.
    Negrini M; Tomasello G; Davidsson M; Fenyi A; Adant C; Hauser S; Espa E; Gubinelli F; Manfredsson FP; Melki R; Heuer A
    J Parkinsons Dis; 2022; 12(4):1133-1153. PubMed ID: 35213388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson's Disease.
    Huang R; Gao Y; Duan Q; Zhang Q; He P; Chen J; Ma G; Wang L; Zhang Y; Nie K; Wang L
    Mol Neurobiol; 2023 Feb; 60(2):979-1003. PubMed ID: 36394710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental exposure to the Parkinson's disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice.
    Boyd SL; Kuhn NC; Patterson JR; Stoll AC; Zimmerman SA; Kolanowski MR; Neubecker JJ; Luk KC; Ramsson ES; Sortwell CE; Bernstein AI
    Toxicol Sci; 2023 Oct; 196(1):99-111. PubMed ID: 37607008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of pSer129-αSyn Pathology and Neurofilament Light-Chain Release across In Vivo, Ex Vivo, and In Vitro Models of Pre-Formed-Fibril-Induced αSyn Aggregation.
    Hansen ML; Ambjørn M; Harndahl MN; Benned-Jensen T; Fog K; Bjerregaard-Andersen K; Sotty F
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo.
    Albert K; Raymundo DP; Panhelainen A; Eesmaa A; Shvachiy L; Araújo GR; Chmielarz P; Yan X; Singh A; Cordeiro Y; Palhano FL; Foguel D; Luk KC; Domanskyi A; Voutilainen MH; Huttunen HJ; Outeiro TF; Saarma M; Almeida MS; Airavaara M
    Mol Ther; 2021 Sep; 29(9):2821-2840. PubMed ID: 33940158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
    Zhou W; Hurlbert MS; Schaack J; Prasad KN; Freed CR
    Brain Res; 2000 Jun; 866(1-2):33-43. PubMed ID: 10825478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C; Papazoglou A; Just L; Nikkhah G
    Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.